Research.Patient.info
Patients with unresectable, previously treated locally advanced or research hub
3 indexed studies · 3 currently recruiting
- recruitingPhase I and Phase II (Integrated)- First administration to humans
A global multicenter phase 1/2 trial of EO4010, a novel microbial-derived peptide therapeutic vaccine, in combination with nivolumab and/or bevacizumab, for treatment of patients with previously treated metastatic colorectal carcinoma (the "AUDREY" study).
This study, called "AUDREY," is for people with bowel cancer that has spread and has been treated before. It tests a new vaccine called EO4010 with existing cancer medicines to see if it's safe and helps improve treatment.
France · Spain - recruitingPHASE1
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This study is testing a new medicine for people with advanced cancers that haven't responded to other treatments. It aims to see how safe the medicine is, how it moves through the body, and what dose works best.
United States · Canada - recruiting
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
This study looks at how a specific treatment (encorafenib and cetuximab) works in real life for advanced bowel cancer with a particular gene change (BRAFV600E mutation). It also checks quality of life, safety, and how well it's tolerated in everyday use.
Austria · Germany